-
Helicobacter pylori positive, can it be cured
Time of Update: 2022-08-11
pylori will not bring adverse consequences;(4) Eradication of Helicobacter pylori is the most important means to prevent intestinal gastric cancer;(5) Hp screening and treatment strategies are recommended in both the population in the high incidence area of gastric cancer and the general community population .
-
Bayer withdraws PI3K inhibitor application for one indication
Time of Update: 2022-05-28
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
-
The seventh batch of national mining, the latest news
Time of Update: 2022-04-25
Compared with the previous arrangement, the progress has been delayed by about two months The above-mentioned person further pointed out that if the centralized procurement documents are successfully released before March, according to the original arrangement, the seventh batch of national procurement will be able to enter the results release stage from April to May .
-
ALS new drug research and development both suffered setbacks: Biogen/Ionis terminated the phase I trial of Amylyx's drug listing, which was questioned by FDA
Time of Update: 2022-04-21
On March 28, Biogen and its partner Ionis Pharmaceuticals released the first-line results of the Phase I clinical trial of BIIB078 .
The FDA questioned the company's ALS treatment AMX0035 on March 28, arguing that data on the drug's effectiveness were inconclusive .
-
The 8MW2311 immune agonist of Maiwei Bio-Injection was approved for clinical use
Time of Update: 2022-03-07
received the "Notice of Acceptance" approved and issued by the State Drug Administration, and the clinical trial application of 8MW2311 for injection was accepted .
8MW2311 for injection is a polyethylene glycol conjugated human interleukin-2 immune agonist for the treatment of advanced malignant tumors .
-
The Phase III pivotal clinical IND of IMG-020 was accepted by CDE
Time of Update: 2022-02-24
On December 23, Chuangxiang Bio announced that the Center for Drug Evaluation (CDE) of the State Drug Administration has officially accepted the IND application of its candidate drug izokibep (IMG-020) for the treatment of plaque psoriasis.
. Previously, Izokibep has successfully completed a phase II clinical study for psoriasis in Germany .
-
Jiangsu Innovative "Trinity" Food Safety Liability Insurance Model
Time of Update: 2022-01-25
Recently, it was learned from the Jiangsu Provincial Market Supervision Bureau that Jiangsu Province has implemented a "three-in-one" food safety liability insurance model with innovative management-side top-level design, supply-side process control, and demand-side result-oriented, and has made great efforts to promote it and achieved remarkable results .
-
NMPA publicly solicits opinions on "Guiding Principles of Pharmacovigilance Inspection (Draft for Comment
Time of Update: 2022-01-02
On December 1, the Comprehensive Department of the State Food and Drug Administration issued an announcement stating that, in order to implement the Pharmaceutical Administration Law of the People’s Republic of China and the Vaccine Administration Law of the People’s Republic of The Bureau organized the drafting of the "Guiding Principles for Pharmacovigilance Inspection (Draft for Soliciting Comments)" (see Annex 1), which is now open to the public for comments .
-
The ban on fertilizer processing trade is lifted again after 13 years
Time of Update: 2021-12-12
" The notice pointed out that 2021 Nian 1 Yue 1 date, processing trade imports of fertilizer must be submitted "automatic import license" to the customs.
" The notice pointed out that 2021 Nian 1 Yue 1 date, processing trade imports of fertilizer must be submitted "automatic import license" to the customs.
-
Announcement of the Center for Drug Evaluation of the State Drug Administration on Issuing the "Technical Guidelines for the Detection of Minimal Residual Diseases in Clinical Trials of Chronic
Time of Update: 2021-12-08
In order to encourage the development of new anti-tumor drugs, under the deployment of the National Medical Products Administration, the Center for Drug Evaluation has organized and formulated the "Technical Guidelines for the Detection of Minimal Residual Diseases in Clinical Trials of Chronic Myeloid Leukemia Drugs" (see appendix) .
-
Announcement of Chongqing Municipal Administration of Market Supervision on the Sampling Inspection of Food Safety of 2671 Batches (No. 62 of 2021
Time of Update: 2021-12-02
(13) The moisture content of dried fungus sold by Xi Nian Dry and Fresh Business Department in Tongnan District did not meet the requirements of national food safety standards .
-
With a series of policies vigorously boosting the development of Chinese medicine, the authentic medicinal material industry has a great opportunity
Time of Update: 2021-11-14
For example, as early as December 18, 2018, the Ministry of Agriculture and Rural Affairs of the United Nations National Drug Administration and the State Administration of Traditional Chinese Medicine jointly issued the "National Authentic Medicinal Material Production Base Construction Plan (2018-2025)", which is a guide Important documents for the development of the Chinese herbal medicine industry in the next few years are also important measures to implement the Chinese Medicine Law .
-
Kehua Biological Serum Amyloid A Determination Kit Obtained Medical Device Registration Certificate
Time of Update: 2021-11-13
On November 3, Kehua Biological issued an announcement stating that the company's product serum amyloid A (SAA) determination kit (chemiluminescence method) received the "Medical Device Registration C
-
Amlodipine benzoate dry suspension, a wholly-owned subsidiary of Poinsettia, obtained the notification of drug clinical trial
Time of Update: 2021-11-05
On September 14, Poinsettia issued an announcement stating that its wholly-owned subsidiary, Poinsettia Pharmaceuticals, declared that the dry suspension of amlodipine benzoate (acceptance number: CXH
-
Huahai Pharmaceuticals Memantine Hydrochloride Tablets Obtained Drug Registration Certificate
Time of Update: 2021-09-13
On August 31, Huahai Pharmaceutical issued an announcement stating that the company had recently received a "drug registration certificate" for memantine hydrochloride tablets approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer's dementia .
